Interim results out from the clinical trial of India's first stem-cell based therapy for Geographic Atrophy- an advanced form of Dry Age Related Macular Degeneration, which is the leading cause of blindness in individuals over 60, impacting ~196 million people globally

Being done by CCAMP startup @EyestemResearch, their innovative product, Eyecyte RPE is an iPSC-derived retinal pigment epithelium, which has shown amazing results in the first set of patient injections

As reported by Eyestem, their stem cell based therapy 
*has been well tolerated across the first two doses with no serious adverse events  and minimal Treatment Emergent Adverse Events,
*has shown vision improvement in 5 out of 6 patients, which has sustained over a period of 5 months. 
*also shown noticeable decrease in the retinal pigment epithelium defect area and the photoreceptor defect area in the injected eye
Know more-As India's first stem cell therapy for a rare eye disease, they are looking to democratise access to cell therapy based solutions for India and beyond and reduce costs for cell therapy by a magnitude of 98%, which are otherwise exorbitantly expensive

Pic credit: Eyestem Research

@Taslimarif @dineshgrao @PriyankKharge @kiranshaw @kris_sg @DrJitendraSingh @rajesh_gokhale @PrinSciAdvGoI @PrinSciAdvOff @DBTIndia @BIRAC_2012 @IndiaDST @AIMtoInnovate @NITIAayog @startupindia @Startup_Kar @ITBTGoK